Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPN1 | P18031 | 1/20 | 0.88 |
| ▸ | PRKCD | Q05655 | 1/20 | 0.69 |
| ▸ | CETP | P11597 | 1/20 | 0.67 |
| ▸ | NT5E | P21589 | 6/20 | 0.66 |
| ▸ | PRKCG | P05129 | 2/20 | 0.60 |
| ▸ | RELA | Q04206 | 1/20 | 0.60 |
| ▸ | NR1H4 | Q96RI1 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2612048 | 0.94 | PTPN1 (0.83) | PTPN1PRKCDCETPNT5EPRKCG | |
| Bevirimat SCHEMBL12465626 | 0.94 | PTPN1 (1.00) | PTPN1PRKCDCETPNT5EPRKCG | |
| Bevirimat SCHEMBL10061308 | 0.94 | PTPN1 (1.00) | PTPN1PRKCDCETPNT5EPRKCG | |
| Bevirimat SCHEMBL19480543 | 0.94 | PTPN1 (1.00) | PTPN1PRKCDCETPNT5EPRKCG | |
| Bevirimat SCHEMBL12565073 | 0.94 | PTPN1 (1.00) | PTPN1PRKCDCETPNT5EPRKCG | |
| SCHEMBL13222940 | 0.94 | PTPN1 (0.91) | PTPN1PRKCDCETPNT5EPRKCG | |
| Bevirimat SCHEMBL2612026 | 0.94 | PTPN1 (1.00) | PTPN1PRKCDCETPNT5EPRKCG | |
| Bevirimat SCHEMBL16272373 | 0.94 | PTPN1 (1.00) | PTPN1PRKCDCETPNT5EPRKCG | |
| SCHEMBL14163456 | 0.93 | PTPN1 (0.87) | PTPN1PRKCDCETPNT5EPRKCG | |
| SCHEMBL13403512 | 0.93 | PTPN1 (0.87) | PTPN1PRKCDCETPNT5EPRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120101098-A1 | 3,28-DISUBSTITUTED BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2012-04-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101098-A1 | 3,28-DISUBSTITUTED BETULINIC ACID DERIVATIVES AS ANTI-HIV AGENTS | BET1, CD4, PGGT1B | PTPN1 4168/4885PRKCD 3984/4885CETP 3658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.